The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation
| Autor: | Rhidian J. Shelton, Kevin Goode, John G.F. Cleland, Andrew L. Clark, Alan S. Rigby |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Diastole Left ventricular hypertrophy Ventricular Dysfunction Left Predictive Value of Tests Internal medicine Atrial Fibrillation Natriuretic Peptide Brain medicine Natriuretic peptide Humans Sinus rhythm cardiovascular diseases Aged Heart Failure business.industry Atrial fibrillation medicine.disease Brain natriuretic peptide Peptide Fragments Echocardiography Heart failure Cardiology Regression Analysis Female Cardiology and Cardiovascular Medicine business Atrial flutter |
| Zdroj: | European Heart Journal. 27:2353-2361 |
| ISSN: | 1522-9645 0195-668X |
| DOI: | 10.1093/eurheartj/ehl233 |
| Popis: | Aims To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of major structural heart disease (MSHD) in patients with atrial fibrillation (AF) compared with those with sinus rhythm (SR) using receiver operator characteristic (ROC) analysis. NT-proBNP is elevated in MSHD and heart failure (HF). AF, a common finding in HF and MSHD, is also associated with raised plasma NT-proBNP. As a result, the utility of NT-proBNP for predicting MSHD may be reduced. Methods and results One thousand four hundred and seventy-six patients underwent assessment at a single centre, performed without the knowledge of NT-proBNP levels. MSHD included left ventricular (LV) systolic and diastolic dysfunctions, left-sided valvular disease, right heart disease (including pulmonary hypertension) and severe LV hypertrophy. One hundred and fifty-five patients were excluded due to renal impairment, atrial flutter, or a pacemaker. Seven hundred and ninety-three patients were diagnosed with MSHD. Median NT-proBNP concentrations for patients with MSHD were 960 (IQR 359–2625) pg/mL and 2491 (1443–4368) pg/mL for SR (n ¼ 591) and AF (n ¼ 202), respectively (P , 0.001). Patients without MSHD had NT-proBNP levels of 179 (90–401) pg/mL and 1000 (659–1760) pg/mL for SR (n ¼ 454) and AF (n ¼ 74), respectively (P , 0.001). The area under the ROC curve for NT-proBNP to detect MSHD was 0.79 for SR (95% CI 0.77–0.82) and 0.78 for AF (95% CI 0.72–0.84). NT-proBNP cut-off levels necessary to achieve a 1 in 100 false negative rate were 27.5 (7.5–30.5) pg/ml and 524 (253–662) pg/ml for SR and AF, respectively. Conclusion NT-proBNP performs as well in patients with SR as in those with AF. However, significantly higher cut-off levels are required for patients with AF to achieve similar levels of diagnostic specificity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|